Cyclosporin A and HIF-1α inhibitors (HIFi) inhibit TGF-β1-induced fibroblast-to-myofibroblast transition, reducing expression levels of α-SMA and fibronectin, and dedifferentiating myofibroblast-like cells (MyoLCs) from pulmonary fibrosis patients [42]. Here, FN1 is linked to pulmonary fibrosis.